entertainment -WSS

entertainment

author：Wikipedia 2025-09-30 09:57:22 - browse：7526

Adobe

WASHINGTON — WuXi Biologics executives have joined the lobbying fray in the lead-up to a move by Congress to add the company to a blacklist meant to prevent certain biotech firms from doing business in the United States.

Legislation proposing that blacklist, known as the BIOSECURE Act, was passed in a 40-1 bipartisan vote on Wednesday by the House Oversight and Accountability Committee. That’s an important development because until now, the House Select Committee on the Chinese Communist Party had handled the bill in the House. That panel is an ad-hoc committee created to build bipartisan consensus on China policies, but it does not have the authority to pass legislation. A Senate committee also passed the BIOSECURE Act nearly unanimously earlier this year.

With the bill out of the Oversight Committee, the goal is for the House to pass it before the July 4 recess. That would set the legislation up to be included in a year-end must-pass legislative package, possibly the National Defense Authorization Act, which Congress has passed every year for decades.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Ebola: Gilead Sciences antiviral shows promise as new treatment

WSS

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Synthetic human embryos? Researchers say term is overblown

GOP hopefuls to address prominent, controversial group questioning what's taught in schools

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

As AI in medicine takes off, can 'human in the loop' prevent harm?

First U.S. drug developed to treat liver disease MASH is approved

entertainment

entertainment

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily intelligence on Capitol Hill and the life sciences industry — by subscribing to STAT+.

Wikipedia

Supreme Court strikes down use of affirmative action

The strange history of BMI, the body mass index

Apple is now the first public company to be valued at $3 trillion

Newly formed Hurricane Beatriz sweeps close to Mexico's southwest Pacific coast

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Why do we get seasonal allergies?

How to save PrEP access — and even expand it

FDA advisers back CAR

Activists slam private health insurers over coverage restrictions

Readout LOUD podcast: ALS dilemma, first MASH drug, and more

entertainment

The simple reason for the increase in autism diagnosis

Change Healthcare outage fallout shows need for new oversight

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

Change Healthcare outage fallout shows need for new oversight

Amylyx ALS drug fails trial: Relyvrio patients react with fear, worry

Federal board approves $12.7 billion budget for Puerto Rico as island shakes off bankruptcy

explore

leisure time

leisure time

leisure time